Non-invasive prenatal diagnosis by massively parallel sequencing of maternal plasma DNA

• Published in: Open biology Vol. 2; no. 6; p. 120086
• Main Author: Lo, Yuk Ming Dennis
• Format: Journal Article
• Language: English
• Published: England The Royal Society 01.06.2012
• Subjects: Aneuploidy; DNA - blood; DNA - genetics; DNA Mutational Analysis - methods; Down Syndrome; Female; Fetus - metabolism; Foetal Dna In Maternal Plasma; Humans; Next-Generation Sequencing; Perspective; Plasma Nucleic Acids; Pregnancy; Prenatal Diagnosis - methods; Trisomy 21; foetal DNA in maternal plasma; Down syndrome; plasma nucleic acids; next-generation sequencing; trisomy 21
• ISSN: 2046-2441; 2046-2441
• DOI: 10.1098/rsob.120086

The presence of foetal DNA in the plasma of pregnant women has opened up new possibilities for non-invasive prenatal diagnosis. The use of circulating foetal DNA for the non-invasive prenatal detection of foetal chromosomal aneuploidies is challenging as foetal DNA represents a minor fraction of maternal plasma DNA. In 2007, it was shown that single molecule counting methods would allow the detection of the presence of a trisomic foetus, as long as enough molecules were counted. With the advent of massively parallel sequencing, millions or billions of DNA molecules can be readily counted. Using massively parallel sequencing, foetal trisomies 21, 13 and 18 have been detected from maternal plasma. Recently, large-scale clinical studies have validated the robustness of this approach for the prenatal detection of foetal chromosomal aneuploidies. A proof-of-concept study has also shown that a genome-wide genetic and mutational map of a foetus can be constructed from the maternal plasma DNA sequencing data. These developments suggest that the analysis of foetal DNA in maternal plasma would play an increasingly important role in future obstetrics practice. It is thus a priority that the ethical, social and legal issues regarding this technology be systematically studied.